Stock Events

Stock Events

Geovax Labs 

€3.74
134
+€0.00+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
93.53
52W Low
3.74
Volume
-
Avg. Volume
0
Mkt Cap
19.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q2 2026
Next
-1.06
-0.99
-0.92
-0.85
Expected EPS
-0.9394710000000001
Actual EPS
N/A

Financials

-834.43%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.24MRevenue
-18.66MNet Income

Analyst Ratings

$0.76Average Price Target
The highest estimate is 0.76.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow E8LA.STU. It's not an investment recommendation.
NVIDIA
31
NVDA
Amazon
23
AMZN
Tesla
21
TSLA
Palantir Technologies
21
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.69B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to GeoVax's focus area.
Moderna
MRNA
Mkt Cap58.11B
Moderna is involved in mRNA-based vaccines, competing in the same space as GeoVax with its focus on innovative vaccine technologies.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech competes with GeoVax in the development of vaccines for infectious diseases, including COVID-19, leveraging mRNA technology.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the vaccine market, including efforts against diseases targeted by GeoVax.
Pfizer
PFE
Mkt Cap162.16B
Pfizer, with its global presence and vaccine portfolio, including a COVID-19 vaccine developed with BioNTech, is a competitor in the vaccine space.
Inovio Pharmaceuticals
INO
Mkt Cap147.86M
Inovio Pharmaceuticals focuses on DNA medicines, including vaccines for infectious diseases, positioning it as a competitor to GeoVax.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline, with a broad portfolio of vaccines, competes in the same market as GeoVax, targeting various infectious diseases.
Sanofi
SNY
Mkt Cap106.01B
Sanofi, through its vaccine division Sanofi Pasteur, is a major player in the vaccine market, competing with GeoVax in several areas.
Arbutus Biopharma
ABUS
Mkt Cap1.02B
Arbutus Biopharma is involved in the development of therapeutic solutions for infectious diseases, indirectly competing with GeoVax's vaccine development efforts.

About

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Show more...
CEO
David Alan Dodd
Employees
19
Country
United States
ISIN
US3736787058
WKN
000A401UX

Listings

MU
DE
E8L.MU
STU
DE
E8LA.STU
MU
DE
E8LA.MU
BOATS
BOATS
GOVX.BOATS

0 Comments

Share your thoughts

FAQ

What is Geovax Labs stock price today?▼
The current price of E8LA.STU is €3.74 EUR — it has increased by +0% in the past 24 hours. Watch Geovax Labs stock price performance more closely on the chart.
What is Geovax Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Geovax Labs stocks are traded under the ticker E8LA.STU.
Is Geovax Labs stock price growing?▼
E8LA.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Geovax Labs has showed a +2,400% increase.
What is Geovax Labs market cap?▼
Today Geovax Labs has the market capitalization of 19.49M
When is the next Geovax Labs earnings date?▼
Geovax Labs is going to release the next earnings report on November 05, 2026.
What were Geovax Labs earnings last quarter?▼
E8LA.STU earnings for the last quarter are -0.85 EUR per share, whereas the estimation was -1.06 EUR resulting in a +19.17% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Geovax Labs revenue for the last year?▼
Geovax Labs revenue for the last year amounts to 2.24M EUR.
What is Geovax Labs net income for the last year?▼
E8LA.STU net income for the last year is -18.66M EUR.
How many employees does Geovax Labs have?▼
As of September 13, 2026, the company has 19 employees.
In which sector is Geovax Labs located?▼
Geovax Labs operates in the Health & Wellness sector.
When did Geovax Labs complete a stock split?▼
The last stock split for Geovax Labs was on January 12, 2026 with a ratio of 1:25.
Where is Geovax Labs headquartered?▼
Geovax Labs is headquartered in SMYRNA, United States.